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Background: Previous findings suggest that apathy symptoms independently of depressive 
symptoms measured using the Geriatric Depression Scale (GDS) are associated with cardio-
vascular disease (CVD) in older individuals.
Aims: To study whether apathy and depressive symptoms in older people are associated with 
future CVD, stroke, and mortality using individual patient-data meta-analysis.
Methods: Medline, Embase, and PsycInfo databases up to September 3, 2013, were systemati-
cally searched without language restrictions. We sought prospective studies with older (mean age 
≥65 years) community-dwelling populations in which the GDS was employed and subsequent 
stroke and/or CVD were recorded to provide individual participant data. Apathy symptoms 
were defined as the three apathy-related subitems of the GDS, with depressive symptoms the 
remaining items. We used myocardial infarction (MI), stroke, and all-cause mortality as main 
outcomes. Analyses were adjusted for age, sex, and MI/stroke history. An adaptation of the 
Newcastle–Ottawa scale was used to evaluate bias. Hazard ratios were calculated using one-
stage random-effect Cox regression models.
Results: Of the 52 eligible studies, 21 (40.4%) were included, comprising 47,625 older people 
(mean age [standard deviation] 74 [7.4] years), over a median follow-up of 8.8 years. Participants 
with apathy symptoms had a 21% higher risk of MI (95% confidence interval [CI] 1.08–1.36), 
a 37% higher risk of stroke (95% CI 1.18–1.59), and a 47% higher risk of all-cause mortality 
(95% CI 1.38–1.56). Participants with depressive symptoms had a comparably higher risk of 
stroke (HR 1.36, 95% CI 1.18–1.56) and all-cause mortality (HR 1.44, 95% CI 1.35–1.53), but 
not of MI (HR 1.08, 95% CI 0.91–1.29). Associations for isolated apathy and isolated depressive 
symptoms were comparable. Sensitivity analyses according to risk of bias yielded similar results.
Conclusion: Our findings stress the clinical importance of recognizing apathy independently 
of depressive symptoms, and could help physicians identify persons at increased risk of vas-
cular disease.
Keywords: apathy, older people, depression, cardiovascular disease, meta-analysis, stroke, 
myocardial infarction
Introduction
A number of meta-analyses have reported that depression in older people is associated 
with an increased risk of cardiovascular disease (CVD).1–4 From a clinical point of view, 
it is important that specific symptom clusters within depression might be differentially 
related to incident CVD.5–7 One such symptom cluster is apathy, generally defined 
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as disrupted motivation, resulting in reduced goal-driven 
behavior, cognition, and emotion, although exact definitions 
vary. We found that in community-dwelling older people, 
a cluster of three motivational symptoms related to apathy 
within the 15-item Geriatric Depression Scale (GDS15)8–10 
was associated with an increased risk of incident CVD. There 
was no such association for the 12 remaining symptoms 
within the GDS15.11
This finding corroborated previously reported associa-
tions of apathy symptoms with a history of stroke, CVD, 
and concurrent cardiovascular (CV) risk factors.8,12 These 
findings are consistent with the “vascular apathy” hypothesis, 
which supposes vascular factors play an important role in 
the etiology of apathy in later life.12 Apathy symptoms can 
occur in both the context of depression and independently 
as an isolated syndrome of disturbed motivation,13 report-
edly occurring in around 10%–20% of community-dwelling 
older people.8,14–16 However, apathy currently receives little 
prominence in diagnostic practice. Determining whether 
community-dwelling older people with apathy symptoms 
have an increased risk of CV events is important, since 
these individuals may be disinclined to engage actively in 
healthy behavior and be easily overlooked in general practice, 
because of a tendency to withdraw from medical care due to 
the nature of the condition.
To corroborate our findings regarding the relation between 
incident CVD and apathy symptoms, external validation is 
essential. For this purpose, the Initiative on Cardiovascular 
Disease Risk and Apathy (ICARA) was set up, which aimed 
to study the independent relationships of apathy and depres-
sive symptoms with myocardial infarction (MI), stroke, and 
mortality risk, by pooling data from longitudinal cohort stud-
ies in community-dwelling older people worldwide. Given 
our previous findings and the vascular apathy hypothesis, we 
hypothesized that apathy and depressive symptoms would be 
independently and differentially associated with MI, stroke, 
and mortality risk.
Methods
We conducted a participant-data meta-analysis in accor-
dance with the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses of Individual Participant Data 
(PRISMA-IPD) guidelines and the recommendations 
made by Riley et al for conducting IPD analyses.17,18 The 
IPD protocol was registered in the PROSPERO database 
(http://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42014013087#.VWSK447tlBc, Supplementary 
materials). This study was judged exempt from review by 
the Amsterdam Academic Medical Center Medical Ethics 
Committee.
Search strategy and selection criteria
Using the Ovid platform, we searched the Medline, Embase, 
and PsycInfo databases up to and including September 3, 
2013. We did not apply any language restrictions or restric-
tions on publication type or year. The full search strategy 
is described in the Supplementary material. In short, we 
used relevant keywords to search for longitudinal studies 
employing any version of the GDS and containing longi-
tudinal data on CVD (including peripheral arterial disease 
[PAD], angina pectoris, and MI) and/or stroke (including 
transient ischemic attack [TIA]). Furthermore, we screened 
the bibliographies of selected papers and contacted inves-
tigators of a potentially eligible study known through 
acquaintance.
We included published original research papers that 
studied samples of community-dwelling older people (mean 
age ≥65 years) representative of the general population, 
employed a GDS version in which the three apathy items 
previously identified through several principal-component 
analyses were included,8,9 and investigated occurrence of 
stroke and/or CVD. There were no restrictions regarding 
duration of follow-up. Studies that included both community-
dwelling and institutionalized participants were eligible only 
if they were able to distinguish between the two. We tried 
to maximize representation for the general population by 
excluding studies that selected participants based on frailty, 
disability, CV-risk profile, or any specific disease. We also 
excluded case–control studies, since the control groups of 
these studies are likely to form a particular selection, rather 
than a cohort representative of the general population. To 
balance the required demands of reference screening, study 
coordination, and data harmonization with the relevance of 
the data contribution we excluded dissertations, conference 
abstracts and studies with a sample size ≤100.
Titles and abstracts of identified papers were screened 
independently by two reviewers (LE, JWD). Full texts of 
selected articles were retrieved and papers reporting on the 
same single study collated. Studies were assessed for eligi-
bility independently by both reviewers. Discrepancies were 
resolved by consensus. A third reviewer was available for 
consultation where agreement could not be reached (ER). 
For studies that were cross-sectional but otherwise eligible, 
PubMed and the Internet were searched for any indication 
of longitudinal follow-up being available for the study 
 population in question. If so, studies were considered eligible. 
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Authors of eligible studies were invited to contribute data for 
our analyses. A reminder was sent after 1 month.
Data, definitions, and statistics
The variables requested and methods used to check data 
integrity are described in the Supplementary materi-
als. Unless reported there, all statistical analyses were 
prespecified.
Apathy and depressive symptoms
We defined apathy symptoms as a score ≥2 on the three apa-
thy items of the GDS15 apathy subscale (GDS3A): “Have 
you dropped many of your activities and interests?”, “Do 
you prefer to stay at home, rather than going out and doing 
new things?”, and “Do you feel full of energy?” (reverse-
coded).8,9 These items have been reported to have a sensitivity 
of 69% and a specificity of 85% to detect apathy based on 
the customary cutoff (>13) of the 14-item apathy scale in 
older adults.12 We defined depressive symptoms as a score 
≥2 on the 12 remaining items of the GDS15 (GDS12D). For 
studies employing GDS versions with >15 items, we selected 
the appropriate three and 12 items. We performed separate 
analyses for apathy symptoms, isolated apathy symptoms 
(concurrent GDS3A ≥2 and GDS12D ≤1), depressive 
symptoms, and isolated depressive symptoms (concurrent 
GDS12D ≥2 and GDS3A ≤1). These cutoffs were based 
on analyses in previous studies.11 We conducted sensitivity 
analyses in which the more specific ≥5 cutoff for GDS12D 
depressive symptoms was used and isolated symptoms were 
defined as a score ≥2 on one subscale and a score of 0 on the 
other. We excluded individuals with more than one missing 
item on the GDS3A and/or more than two missing items 
on the GDS12D from the analyses. Post hoc, a sensitivity 
analysis was performed with apathy and depressive scores 
as continuous predictors.
Outcomes
We used time to first fatal or nonfatal MI, first fatal or 
nonfatal stroke (TIA excluded), and mortality as primary 
outcomes. Regarding MI and stroke events, these could be 
both first ever (i.e. incident) or recurrent. Mixed-model Cox 
proportional-hazard regression was used to calculate hazard 
ratios (HRs). Mixed-model logistic regression analyses 
were used to repeat the primary analyses on MI and stroke 
with the inclusion of studies in which dates of events were 
unavailable. A sensitivity analysis was conducted, including 
TIA. Finally, in order to compare results with those of our 
previous studies, a composite CVD outcome  comprising 
myocardial infarction (MI), angina pectoris (AP) and 
peripheral arterial disease (PAD) was analyzed.11 Because 
an exact date of onset may be difficult to establish in cases 
of AP and PAD, these analyses were performed using 
logistic regression models. Subanalyses were conducted 
for CV mortality (primary CV cause of death according to 
the ICD9 [390–459] or -10 [I00–I99]) and non-CV mortal-
ity (all other causes) separately. A detailed description of 
how vascular variables were harmonized is provided in 
the Supplementary material. To assess how HRs differed 
among studies, we plotted and pooled the separate results 
of fixed-effect Cox analyses in each study for all primary 
outcomes, using inverse variance-weighted DerSimonian 
and Laird random-effect models. To quantify heterogeneity, 
I2 statistics were used.
Confounders and interaction
Three models were assessed for each outcome. Model 1 
was unadjusted, model 2 adjusted for age and sex (in logis-
tic regression additionally for study follow-up duration), 
and model 3 additionally adjusted for history of MI and/or 
stroke, because these may be confounders in the relationship 
of apathy and depressive symptoms with each outcome.11 
Interaction analyses were performed to evaluate possible 
moderation by age, sex, and history of MI and/or stroke. To 
examine the effect of age on the observed relations in more 
detail, we performed subgroup analyses within tertiles based 
on age. Furthermore, subgroup analyses were performed in 
individuals without a history of MI and/or stroke to facilitate 
comparison with our previous analyses.11
Statistical analysis
Random-effect Cox proportional-hazard regression analy-
ses were performed in R (version 3.2) using the Coxme 
package.19,20 Overall HRs for the IPD meta-analyses were 
calculated using a one-stage random-effect model, with 
independent random slopes in each study for each predictor 
to account for clustering of participants (ie, clusters based 
on study).21 For binary logistic regression analyses, similar 
models were used, employing the Lme4 package.22 The R 
codes used are described in more detail in the Supplementary 
material. Statistical analyses were two-tailed, and significance 
was set at α=0.05. We plotted and pooled HRs within indi-
vidual studies using the Meta package.23
Bias assessment
We assessed availability bias by comparing distributions of 
age, sex, and population sizes of participating and nonpartici-
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pating studies. Risk of bias was evaluated per study using an 
adapted version of the Newcastle–Ottawa  quality-assessment 
scale for cohort studies,24 based on the following characteris-
tics: method of outcome assessment for MI and stroke (self-
report only vs other methods); proportion with missing status 
with regard to occurrence of MI, stroke, and mortality (lower 
vs higher than the median proportion for that outcome); 
study design (observational vs experimental); and selected vs 
general populations according to independent evaluation by 
two reviewers (LE, JWD), with selection based on age (≥80 
years only), sex, and/or recruitment strategy (specific sample 
types) (Table S1). Discrepancies were resolved by consensus 
and consultation with a third author (WAG) if necessary. 
Sensitivity analyses comparing studies with lower vs higher 
risk of bias were performed for each primary outcome for 
each criterion.
Results
Search results are depicted in Figure 1. A total of 21 (40.4% 
of eligible) studies participated,25–45 comprising data from 
Figure 1 PRISMA diagram of study selection.
Notes: aDissertation/conference abstract, ≤100 study participants, no longitudinal data, case–control study, no original data, no geriatric depression scale or geriatric 
depression scale version without apathy items; bone dissertation, one study with ≤100 participants, and full text not available for one study.
1,643 records identified through database searching
1,260 records after duplicate removal
1,260 records screened
1,053 records excluded based on review of titles
and abstractsa
207 full-text articles assessed for eligibility
207 articles linked to 108 unique studies
56 studies excluded after full review
52 studies for which individual participant data
were sought
21 studies provided individual participant data:
  12,956 study participants for whom data were missing/
  inappropriate (no geriatric depression scale score,
  not community-dwelling, no retrievable case-report forms)
  48,429 study participants for whom data were provided
  804 no available apathy and depressive score
  47,625 study participants included in analyses
31 studies for which individual participant data were not provided
  52.536 participants
    22 no response received
    5 inability to provide suitable data (eg. not longitudinal)
    2 data not available anymore
    2 inability to provide data within time frame of meta-analysis
Time-to-event analysis on myocardial infarction
  8 studies included in analysis
  21,377 participants included in analysis
  26,248 participants excluded from analysis (no [time-to-event] data
  on subsequent myocardial infarction)
Time-to-event analysis on stroke
  10 studies included in analysis
  23,337 participants included in analysis
  24,288 participants excluded from analysis (no [time-to-event] data
  on subsequent stroke)
Time-to-event analysis on mortality
  21 studies included in analysis
  46,859 participants included in analysis
  766  participants excluded from analysis (no [time-to-event] data
  on mortality)
21 other study population
4 no geriatic depression scale or apathy items
2 no original data
26 no longitudinal data
3 otherb
10 additional records identified through other sources
(references, personal knowledge)
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48,429 community-dwelling older people. One study used a 
slightly modified apathy item on the GDS15. Another study 
could only provide data on apathy, not on the depression 
items of the GDS15 (Supplementary material). After exclud-
ing participants with neither apathy nor depression scores 
(n=804), the final sample consisted of 47,625 older (mean 
age 74±7.4 [range 53–105] years) community-dwelling 
people (51.5% women). The median follow-up for mortal-
ity was 8.8 years, yielding 360,306 person-years in total. In 
total, 31.1% (14,788 of 47,566) of participants had apathy 
symptoms, 32.4% (15,093 of 46,624) depressive symptoms, 
13.8% (6,541 of 47,243) isolated apathy symptoms, 15.3% 
(7,169 of 46,947) isolated depressive symptoms, and 16.7% 
(7,911 of 47,276) both. Table 1 describes the general char-
acteristics of the individual study and total ICARA samples. 
Table S1 describes details on study design, in/exclusion 
criteria, recruitment strategy, and MI and stroke assessment.
Outcomes
Time-to-event data were available for stroke in ten (n=23,337) 
and for MI in eight (n=21,377) studies. MI occurred in 5.7% 
(1,217) and stroke in 6.2% (1,452) of individuals. For par-
ticipants with and without apathy symptoms, average 5-year 
risk was 27% vs 16.3% for mortality, 6% vs 3.9% for MI, 
and 7.4% vs 4.2% for stroke, respectively. Average 5-year 
risk comparing participants with and without depressive 
symptoms was 24.7% vs 17.3% for mortality, 4.5% vs 4.6% 
for MI, and 6.4% vs 4.8% for depressive symptoms, respec-
tively. Data on fatal and nonfatal events were provided by 
all except two studies, which only supplied data on nonfatal 
events.27,45 No violations of the proportional-hazard assump-
tion were identified through evaluation of survival curves 
and Schönfeld residuals. Adjusted for age, sex, and history 
of MI and/or stroke, presence of apathy symptoms increased 
the hazard of future MI by 21% (HR 1.21, 95% confidence 
interval [CI] 1.08–1.36) and future stroke by 37% (HR 
1.37, 95% CI 1.18–1.59) (Table 2). Depressive symptoms 
similarly increased the hazard of future stroke by 36% (HR 
1.36, 95% CI 1.18–1.56), but increased the hazard of MI 
less substantially by 8%, with CIs overlapping 0 (HR 1.08, 
95% CI 0.91–1.29). Results for isolated apathy and isolated 
depressive symptoms were comparable to those for apathy 
and depressive symptoms, respectively.
Sensitivity analyses including TIA in analyses of stroke 
gave similar results (Table S2). Results of analyses using 
logistic regression instead of Cox regression models (allow-
ing for four additional studies for MI and two for stroke) were 
also comparable (Table S3). The association between stroke 
and depressive symptoms was slightly attenuated when the 
GDS12D ≥5 cutoff for depressive symptoms was applied. 
A stricter definition for isolated symptoms (0 points on the 
other subscale) slightly attenuated the association for isolated 
apathy symptoms with future MI and stroke (Tables S4 and 
S5). The hazard for the composite outcome of occurrence of 
MI, AP, and/or PAD was 33% (95% CI 1.20-–1.49) higher 
for participants with apathy symptoms compared to those 
without and 8% for participants with depressive symptoms, 
with CIs overlapping 0 (95% CI 0.85–1.37) (Table S6).
Time-to-event data with regard to all-cause mortality were 
provided by all studies (n=46,859). During follow-up, 33.3% 
(15,626) of participants died. In the fully adjusted models, 
both apathy symptoms (HR 1.47, 95% CI 1.38–1.56) and 
depressive symptoms (HR 1.44, 95% CI 1.35–1.53) increased 
the hazard of mortality by nearly 50% (Table 2). Associations 
for isolated apathy and depressive symptom were similar.
Sensitivity analyses using the stricter isolated symptom 
definition and those using the GDS12D ≥5 cutoff for depres-
sive symptoms gave comparable results regarding mortality 
(Tables S7 and S8). ICD codes regarding cause of death 
were provided by 12 studies. HRs for apathy and depres-
sive symptoms seemed slightly higher for non-CV (apathy 
HR 1.45 [95% CI 1.34–1.57]; depressive HR 1.50 [95% CI 
1.35–1.66]) compared to CV mortality (apathy HR 1.38 [95% 
CI 1.16–1.66]; depressive HR 1.33 [95% CI 1.18–1.51]), and 
CIs of the estimates overlapped (Table S9).
When apathy symptoms were explored as categorical 
predictors, a dose–response relationship between increasing 
apathy scores and increasing HRs was found for all outcomes 
(Figure 2). Pooled analyses of HRs in individual studies gave 
similar results to the one-stage approach (summarized in 
Table 3, forest plots in Figures S1–S3). Heterogeneity was 
low in analyses of MI (apathy I2=13%, depressive I2=12%, 
isolated apathy I2=37%, isolated depressive I2=0), low in 
analyses of stroke (all I2=0), and moderate in analyses of 
mortality for overall symptoms (apathy I2=47%, depressive 
I2=50%), while low for isolated symptoms (both I2=0). Funnel 
plots of these analyses showed no indication of publication 
bias (Figures S4–S6).
Interaction
We observed interactions between age and (isolated) depres-
sive symptoms (HR 0.98, 95% CI 0.96–0.99; isolated symp-
toms, HR 0.97, 95% CI 0.94–0.99) in their relationship with 
stroke. This suggests that the relation between (isolated) 
depressive symptoms and future stroke is stronger in younger 
participants. These interactions were consistently present 
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across studies (I2=0). Interaction effects between age and 
both apathy and depressive symptoms (both HRs 0.99, 95% 
CI 0.98–0.99) were present for mortality, suggesting the 
relationships were stronger in younger individuals. These 
interactions were also consistent across studies (apathy symp-
toms, I2=32.4%; depressive symptoms, I2=22.9%). Inclusion 
of these interaction terms into the fully adjusted models 
did not meaningfully alter any of the conclusions (data not 
shown). In subgroup analyses within tertiles based on age 
(<72, 72–77, >77 years), the relationship between apathy 
and both MI and stroke was stronger in older subgroups. 
The relationship between depressive symptoms and stroke 
appeared stronger in younger subgroups (Tables S10–S12) 
Subanalyses in participants without a history of MI and/or 
stroke gave results similar to the main analyses (Tables S13 
and S14).
Table 1 Characteristics of total ICARA population and individual study samples included in ICARAa
Study Region GDS-
examination 
date
Participants, n Age, mean 
(SD), years
Women, n/total (%) Baseline apathy 
symptoms  
(GDS3A ≥2),  
n/total (%)
Baseline depressive 
symptoms  
(GDS12D ≥2),  
n/total (%)
History of MI  
and/or stroke,  
n/total (%)
Subsequent  
MI, n/total (%)
Subsequent 
stroke,  
n/total (%)
Deceased,  
n/total (%)
Follow-up  
mortality,  
median (IQR), 
yearsg
Total ICARA population 1990–2014 47,625 74 (7.4) 24,544/47,625 (51.5) 14,788/47,566 (31.1) 15,093/46,624 (32.4) 4,987/39,297 (12.7) 1,217/21,377 (5.7)b 1,452/23,337 (6.2)b 15,626/46,859 (33.3) 8.8 (5.3–10.9)
Median (IQR) across studies 1,735 (958–3,303) 74.4 (72.2–78.3) 56.6% (48.6%–61.2%) 31.8% (21.4%–42.2%) 31.3% (21.1%–47.3%) 13.6% (7.7%–18.2%) 3.3% (2.3%–9.1%)b 5% (3.4%–7.3%)b 38.1% (22.8%–48.6%) 8.5 (5–11.2)
BELFRAIL study (BFC80+)25 Belgium 2008–2009 499 84 (3.5) 302/499 (60.5) 205/499 (41.1) 186/499 (37.3) 89/481 (18.5) 12/434 (2.8)c 25/445 (5.6)c 201/499 (40.3) 5.1 (5–5.3)
Canadian Study on Health and Aging (CSHA)26 Canada 1995–1997 1,514 82.5 (6.7) 874/1,514 (57.7) 540/1,512 (35.7) 486/1,510 (32.2) – – – 529/1,357 (39) 5 (4.7–5.2)
Einstein Aging Study (EAS)27 USA 1998–2014 1,924 78.2 (5.4) 1,189/1,924 (61.8) 727/1,924 (37.8) 562/1,922 (29.2) 348/1,924 (18.1) 22/948 (2.3)c 37/960 (3.9)c 732/1,920 (38.1) 8 (0–16)
Health in Men Study (HIMS)28 Australia 2001–2004 5,519 76.8 (3.7) 0/5,519 (0) 2,372/5,517 (43) 1,223/5,510 (22.2) 1,010/5,519 (18.3)e 623/5,519 (11.3)c 600/5,501 (10.9)c 1,653/5,519 (30) 7.4 (6.7–8.1)
Health, Well-Being, and Aging Study – Brazil 
(SABE)29
Brazil 2000 1,863 72.1 (7.8) 1,094/1,863 (58.7) 379/1,862 (20.4) 824/1,777 (46.4) – – 138/1,020 (13.5)d 814/1,690 (48.2) 10.7 (10.4–10.9)
Hertfordshire Cohort Study (HCS)30 England 1995–1996 882 68.4 (2.8) 340/882 (38.5) 175/882 (19.8) 154/882 (17.5) – – – 350/874 (40) 15.1 (14.7–15.4)
Hong Kong Old-Old Study (HKOOS)31 China 1991–1992 1,540 77.8 (6.2) 693/1,540 (45) 1,050/1,540 (68.2) 1,210/1,540 (78.6) – – – 712/1,457 (48.9) 4.7 (3–10.2)
Insufficienza Cardiaca negli Anziani Residenti a 
Dicomano study (ICARe Dicomano)32
Italy 1995–1996 634 73.7 (6.4) 374/634 (59) 189/634 (29.8) –f – – – 177/634 (27.9) 8.5 (8.3–8.5)
Intervention Project on Cerebrovascular 
Diseases and Dementia in the Ebersberg 
District (INVADE)33
Germany 2001–2003 3,837 67.1 (7.7) 2,256/3,857 (58.8) 1,571/3,801 (41.3) 880/3,797 (23.2) 276/3,818 (7.2) 89/3,837 (2.3)c 202/3,837 (5.3)c 876/3,837 (22.8) 11.2 (10.1–11.6)
Invecchiamento Cerebrale in Abbiategrasso 
study (InveCe.Ab)34
Italy 2009–2011 1,262 72.2 (1.3) 680/1,262 (53.9) 140/1,262 (11.1) 417/1,262 (33) 171/1,260 (13.6)e 17/1,074 (1.6)d 14/1,059 (1.3)c 45/1,262 (3.6) 2.2 (2.1–2.3)
Italian Longitudinal Study on Aging (ILSA)35 Italy 1992–1993 3,342 74.4 (5.6) 1,578/3,342 (47.2) 1,059/3,329 (31.8) 1,767/3,129 (56.5) 405/3,340 (12.1) 118/3,124 (3.8)c 147/3,126 (4.7)c 1,258/3,125 (40.3) 8.1 (3.6–8.5)
Leiden 85-Plus study (L85+)36 the Netherlands 1997–1999 445 85 (0) 275/445 (61.8) 113/445 (25.4) 110/445 (24.7) 69/440 (15.7) 43/443 (9.7)c 45/445 (10.1)c 424/445 (95.3) 13.5 (12.9–13.9)
Mr Os and Ms Os study (MrMs Os)37 China 2001–2003 3,998 72.3 (5.2) 1,999/3,998 (50) 895/3,998 (22.4) 1,893/3,998 (47.3) 545/3,998 (13.6)e 81/3,997 (2)c 173/3,997 (4.3)c 970/3,998 (24.3) 11.3 (10.7–11.8)
Osservatorio Geriatrico Regione Campania 
study (OGC)38
Italy 1990–1991 1,250 74.1 (6.3) 707/1,250 (56.6) 682/1,250 (54.6) 883/1,250 (70.6) – – – 658/1,250 (52.6) 12.2 (12.2–12.2)
Outcomes of Sleep Disorders in Older Men 
study (MrOS Sleep)39
USA 2003–2005 3,130 76.4 (5.6) 0/3,130 (0) 928/3,129 (29.7) 503/3,130 (16.1) 625/3,130 (20) 229/3,075(7.4)c 194/3,074 (6.3)c 1,055/3,029 (34.8) 9.5 (9.3–9.8)
Selenium and Cognitive Decline Study (SCDS)40 China 2006–2007 1,735 73.8 (5.3) 926/1,735 (53.4) 901/1,735 (51.9) 988/1,735 (56.9) 90/1,733 (5.2) – – 304/1,712 (17.8) 4.5 (4.5–4.5)
Singapore Longitudinal Ageing Study I (SLAS I)41 Singapore 2003–2005 2,789 66.0 (7.7) 1,760/2,789 (63.1) 239/2,788 (8.6) 844/2,788 (30.3) 188/2,785 (6.8)e – – 327/2,789 (11.7) 9.9 (9–10.6)
Singapore Longitudinal Ageing Study II (SLAS II)42 Singapore 2008–2013 3,263 67.0 (7.9) 2,041/3,263 (62.5) 70/3,263 (2.1) 365/3,263 (11.2) 253/3,261 (7.8)e – – 142/3,263 (4.4) 3.6 (2.5–5)
Study of Osteoporotic Fractures (SOF)43 USA 1991–1994 6,591 76.7 (4.8) 6,591/6,591 (100.0) 1,811/6,591 (27.5) 1364/6,583 (20.7) 767/6,588 (11.6)e 463/6,187 (7.5)d – 3,797/6,591 (57.6) 15.7 (13.5–16.5)
Sydney Memory and Ageing Study (MAS)44 Australia 2005–2007 1,033 78.3 (4.8) 569/1,033 (55.1) 504/1,030 (48.9) 162/1,029 (15.7) 151/1,020 (14.8) 27/893 (3)d 15/893 (1.7)c 235/1,033 (22.7) 7 (5.8–7.1)
Treviso Longeva study (Trelong)45 Italy 2003–2004 575 82.3 (7.7) 296/575 (51.5) 238/575 (41.1) 272/575 (47.3) – 11/300 (3.7)d 16/300 (5.3)d 367/575 (63.8) 10.4 (10.1–10.8)
Notes: aStudy samples included in the meta-analyses consisted of community-dwelling individuals with an available apathy and/or depression score. All samples population-
based. bNumbers concern only studies included in time-to-event analysis. cStudy included in time-to-event analysis and logistic regression analysis. dStudy included in logistic 
regression analysis only. eIf a history of stroke excluding TIA was not available to create the composite variable history of MI and/or stroke, a history of stroke including 
TIA was used instead if available. fDue to time constraints in digitalizing individual GDS items from paper case-record forms, the ICARe Dicomano study provided data on 
the GDS3A items only within the time frame of this meta-analysis. gMedian of mortality follow-up calculated excluding deceased individuals. Number of participants with 
missing data within each study sample: age – CSHA 6; baseline apathy score – CSHA 2, HIMS 2, ILSA 13, INVADE 36, MAS 3, MrOS Sleep 1, SABE-Brazil 1, SLAS I 1; baseline 
depression score – CSHA 4, EAS 2, HIMS 9, ICARe Dicomano634 (not available [NA]), ILSA 213, INVADE 40, MAS 4, SABE 86, SLAS I 1, SOF 8; history of MI and/or 
stroke – BFC80+ 18, CSHA 1,514 (NA), HCS 882 (NA), HKOOS 1,540 (NA), ICARe Dicomano 634 (NA), ILSA 2, INVADE 19, InveCe.Ab 2, L85+ 5, MAS 13, OGC 1,250 
(NA), SABE-1,863 (NA), SCDS 2, SLAS1 4, SLAS2 2, SOF 3, Trelong 575 (NA); subsequent MI – BFC80+ 65 (time to event [TTE] and logistic [L]), CSHA 1,514 (NA), EAS 
976 (TTE + L), HCS 882 (NA), HKOOS 1,540 (NA), ICARe Dicomano 634 (NA), ILSA 218 (TTE + L), InveCe.Ab 188 (L), L85+ 2 (TTE + L), MAS 140 (L), MrMs Os 1 (TTE + 
L), MrOS Sleep 55 (TTE + L), OGC 1,250 (NA), SABE 1,863 (NA), SCDS 1,735 (NA), SLAS1 2,789 (NA), SLAS2 3,263 (NA), SOF 404 (L), Trelong 275 (L); subsequent 
stroke – BFC80+ 54 (TTE + L), CSHA 1,514 (NA), EAS 964 (TTE+L), HCS 882 (NA), HIMS 18 (TTE + L), HKOOS 1,540 (NA), ICARe Dicomano 634 (NA), ILSA 216 (TTE 
+ L), InveCe.Ab 203 (TTE + L), MAS 140 (TTE + L), MrMs Os 1 (TTE + L), MrOS Sleep 56 (TTE + L), OGC 1,250 (NA), SCDS 1,735 (NA), SABE 843 (L), SLAS1 2,789 (NA), 
SLAS2 3,263 (NA), SOF 6,591 (NA), Trelong 275 (L); number deceased – CSHA 1,57, EAS 4, HCS 8, HKOOS 83, ILSA 217, MrOS Sleep 101, SABE 173, SCDS23.
Abbreviations: GDS, Geriatric Depression Scale; MI, myocardial infarction; TIA, transient ischemic attack; ICARA, Initiative on Cardiovascular Disease Risk and Apathy.
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Risk of bias
Overall, studies that did not participate in ICARA (n=31) 
were smaller than those included (n=21), had slightly older 
study populations, and included relatively more women 
(Supplementary material). Sensitivity analyses comparing 
studies with higher versus lower risk of bias generally did not 
give any substantial deviations from the main analysis results, 
with association magnitudes being similar (Tables S15–S21). 
However, the evidence was poor in some categorizations, due 
to substantially smaller sample sizes (eg, experimental study 
designs [Table S15], self-reported outcomes [Table S19], and 
high percentage of missing outcomes [Table S20]). Sensitiv-
ity analyses with apathy and depressive-symptom scores as 
continuous predictors (Table S22) showed similar results: in 
models adjusted for age, sex, and history of MI and/or stroke, 
the hazard for participants with apathy symptoms for future 
MI increased, with an 11% per point increase (HR 1.11, 95% 
CI 1.04–1.17), for stroke with a 15% per point increase (HR 
1.15, 95% CI 1.05–1.26), and for mortality with a 24% per 
point increase (HR 1.24, 95% CI 1.20-–1.28). Associations 
were comparable for isolated apathy symptoms. Depressive 
symptoms gave a 5% increase per point for future stroke (HR 
1.05, 95% CI 1.00–1.10) and 9% for mortality (HR 1.09, 95% 
CI 1.07–1.11). The hazard of MI increased less substantially, 
by 3% per point increase, with CIs overlapping 0 (HR 1.03, 
95% CI 0.99–1.08).
Availability of data
The data used in this paper are available from each individual 
participating study. However, restrictions apply to the avail-
ability of these data, which are not publicly available and were 
used under license for the current study. Data are however 
available from the authors upon reasonable request and with 
the permission of each individual study included.
Table 1 Characteristics of total ICARA population and individual study samples included in ICARAa
Study Region GDS-
examination 
date
Participants, n Age, mean 
(SD), years
Women, n/total (%) Baseline apathy 
symptoms  
(GDS3A ≥2),  
n/total (%)
Baseline depressive 
symptoms  
(GDS12D ≥2),  
n/total (%)
History of MI  
and/or stroke,  
n/total (%)
Subsequent  
MI, n/total (%)
Subsequent 
stroke,  
n/total (%)
Deceased,  
n/total (%)
Follow-up  
mortality,  
median (IQR), 
yearsg
Total ICARA population 1990–2014 47,625 74 (7.4) 24,544/47,625 (51.5) 14,788/47,566 (31.1) 15,093/46,624 (32.4) 4,987/39,297 (12.7) 1,217/21,377 (5.7)b 1,452/23,337 (6.2)b 15,626/46,859 (33.3) 8.8 (5.3–10.9)
Median (IQR) across studies 1,735 (958–3,303) 74.4 (72.2–78.3) 56.6% (48.6%–61.2%) 31.8% (21.4%–42.2%) 31.3% (21.1%–47.3%) 13.6% (7.7%–18.2%) 3.3% (2.3%–9.1%)b 5% (3.4%–7.3%)b 38.1% (22.8%–48.6%) 8.5 (5–11.2)
BELFRAIL study (BFC80+)25 Belgium 2008–2009 499 84 (3.5) 302/499 (60.5) 205/499 (41.1) 186/499 (37.3) 89/481 (18.5) 12/434 (2.8)c 25/445 (5.6)c 201/499 (40.3) 5.1 (5–5.3)
Canadian Study on Health and Aging (CSHA)26 Canada 1995–1997 1,514 82.5 (6.7) 874/1,514 (57.7) 540/1,512 (35.7) 486/1,510 (32.2) – – – 529/1,357 (39) 5 (4.7–5.2)
Einstein Aging Study (EAS)27 USA 1998–2014 1,924 78.2 (5.4) 1,189/1,924 (61.8) 727/1,924 (37.8) 562/1,922 (29.2) 348/1,924 (18.1) 22/948 (2.3)c 37/960 (3.9)c 732/1,920 (38.1) 8 (0–16)
Health in Men Study (HIMS)28 Australia 2001–2004 5,519 76.8 (3.7) 0/5,519 (0) 2,372/5,517 (43) 1,223/5,510 (22.2) 1,010/5,519 (18.3)e 623/5,519 (11.3)c 600/5,501 (10.9)c 1,653/5,519 (30) 7.4 (6.7–8.1)
Health, Well-Being, and Aging Study – Brazil 
(SABE)29
Brazil 2000 1,863 72.1 (7.8) 1,094/1,863 (58.7) 379/1,862 (20.4) 824/1,777 (46.4) – – 138/1,020 (13.5)d 814/1,690 (48.2) 10.7 (10.4–10.9)
Hertfordshire Cohort Study (HCS)30 England 1995–1996 882 68.4 (2.8) 340/882 (38.5) 175/882 (19.8) 154/882 (17.5) – – – 350/874 (40) 15.1 (14.7–15.4)
Hong Kong Old-Old Study (HKOOS)31 China 1991–1992 1,540 77.8 (6.2) 693/1,540 (45) 1,050/1,540 (68.2) 1,210/1,540 (78.6) – – – 712/1,457 (48.9) 4.7 (3–10.2)
Insufficienza Cardiaca negli Anziani Residenti a 
Dicomano study (ICARe Dicomano)32
Italy 1995–1996 634 73.7 (6.4) 374/634 (59) 189/634 (29.8) –f – – – 177/634 (27.9) 8.5 (8.3–8.5)
Intervention Project on Cerebrovascular 
Diseases and Dementia in the Ebersberg 
District (INVADE)33
Germany 2001–2003 3,837 67.1 (7.7) 2,256/3,857 (58.8) 1,571/3,801 (41.3) 880/3,797 (23.2) 276/3,818 (7.2) 89/3,837 (2.3)c 202/3,837 (5.3)c 876/3,837 (22.8) 11.2 (10.1–11.6)
Invecchiamento Cerebrale in Abbiategrasso 
study (InveCe.Ab)34
Italy 2009–2011 1,262 72.2 (1.3) 680/1,262 (53.9) 140/1,262 (11.1) 417/1,262 (33) 171/1,260 (13.6)e 17/1,074 (1.6)d 14/1,059 (1.3)c 45/1,262 (3.6) 2.2 (2.1–2.3)
Italian Longitudinal Study on Aging (ILSA)35 Italy 1992–1993 3,342 74.4 (5.6) 1,578/3,342 (47.2) 1,059/3,329 (31.8) 1,767/3,129 (56.5) 405/3,340 (12.1) 118/3,124 (3.8)c 147/3,126 (4.7)c 1,258/3,125 (40.3) 8.1 (3.6–8.5)
Leiden 85-Plus study (L85+)36 the Netherlands 1997–1999 445 85 (0) 275/445 (61.8) 113/445 (25.4) 110/445 (24.7) 69/440 (15.7) 43/443 (9.7)c 45/445 (10.1)c 424/445 (95.3) 13.5 (12.9–13.9)
Mr Os and Ms Os study (MrMs Os)37 China 2001–2003 3,998 72.3 (5.2) 1,999/3,998 (50) 895/3,998 (22.4) 1,893/3,998 (47.3) 545/3,998 (13.6)e 81/3,997 (2)c 173/3,997 (4.3)c 970/3,998 (24.3) 11.3 (10.7–11.8)
Osservatorio Geriatrico Regione Campania 
study (OGC)38
Italy 1990–1991 1,250 74.1 (6.3) 707/1,250 (56.6) 682/1,250 (54.6) 883/1,250 (70.6) – – – 658/1,250 (52.6) 12.2 (12.2–12.2)
Outcomes of Sleep Disorders in Older Men 
study (MrOS Sleep)39
USA 2003–2005 3,130 76.4 (5.6) 0/3,130 (0) 928/3,129 (29.7) 503/3,130 (16.1) 625/3,130 (20) 229/3,075(7.4)c 194/3,074 (6.3)c 1,055/3,029 (34.8) 9.5 (9.3–9.8)
Selenium and Cognitive Decline Study (SCDS)40 China 2006–2007 1,735 73.8 (5.3) 926/1,735 (53.4) 901/1,735 (51.9) 988/1,735 (56.9) 90/1,733 (5.2) – – 304/1,712 (17.8) 4.5 (4.5–4.5)
Singapore Longitudinal Ageing Study I (SLAS I)41 Singapore 2003–2005 2,789 66.0 (7.7) 1,760/2,789 (63.1) 239/2,788 (8.6) 844/2,788 (30.3) 188/2,785 (6.8)e – – 327/2,789 (11.7) 9.9 (9–10.6)
Singapore Longitudinal Ageing Study II (SLAS II)42 Singapore 2008–2013 3,263 67.0 (7.9) 2,041/3,263 (62.5) 70/3,263 (2.1) 365/3,263 (11.2) 253/3,261 (7.8)e – – 142/3,263 (4.4) 3.6 (2.5–5)
Study of Osteoporotic Fractures (SOF)43 USA 1991–1994 6,591 76.7 (4.8) 6,591/6,591 (100.0) 1,811/6,591 (27.5) 1364/6,583 (20.7) 767/6,588 (11.6)e 463/6,187 (7.5)d – 3,797/6,591 (57.6) 15.7 (13.5–16.5)
Sydney Memory and Ageing Study (MAS)44 Australia 2005–2007 1,033 78.3 (4.8) 569/1,033 (55.1) 504/1,030 (48.9) 162/1,029 (15.7) 151/1,020 (14.8) 27/893 (3)d 15/893 (1.7)c 235/1,033 (22.7) 7 (5.8–7.1)
Treviso Longeva study (Trelong)45 Italy 2003–2004 575 82.3 (7.7) 296/575 (51.5) 238/575 (41.1) 272/575 (47.3) – 11/300 (3.7)d 16/300 (5.3)d 367/575 (63.8) 10.4 (10.1–10.8)
Notes: aStudy samples included in the meta-analyses consisted of community-dwelling individuals with an available apathy and/or depression score. All samples population-
based. bNumbers concern only studies included in time-to-event analysis. cStudy included in time-to-event analysis and logistic regression analysis. dStudy included in logistic 
regression analysis only. eIf a history of stroke excluding TIA was not available to create the composite variable history of MI and/or stroke, a history of stroke including 
TIA was used instead if available. fDue to time constraints in digitalizing individual GDS items from paper case-record forms, the ICARe Dicomano study provided data on 
the GDS3A items only within the time frame of this meta-analysis. gMedian of mortality follow-up calculated excluding deceased individuals. Number of participants with 
missing data within each study sample: age – CSHA 6; baseline apathy score – CSHA 2, HIMS 2, ILSA 13, INVADE 36, MAS 3, MrOS Sleep 1, SABE-Brazil 1, SLAS I 1; baseline 
depression score – CSHA 4, EAS 2, HIMS 9, ICARe Dicomano634 (not available [NA]), ILSA 213, INVADE 40, MAS 4, SABE 86, SLAS I 1, SOF 8; history of MI and/or 
stroke – BFC80+ 18, CSHA 1,514 (NA), HCS 882 (NA), HKOOS 1,540 (NA), ICARe Dicomano 634 (NA), ILSA 2, INVADE 19, InveCe.Ab 2, L85+ 5, MAS 13, OGC 1,250 
(NA), SABE-1,863 (NA), SCDS 2, SLAS1 4, SLAS2 2, SOF 3, Trelong 575 (NA); subsequent MI – BFC80+ 65 (time to event [TTE] and logistic [L]), CSHA 1,514 (NA), EAS 
976 (TTE + L), HCS 882 (NA), HKOOS 1,540 (NA), ICARe Dicomano 634 (NA), ILSA 218 (TTE + L), InveCe.Ab 188 (L), L85+ 2 (TTE + L), MAS 140 (L), MrMs Os 1 (TTE + 
L), MrOS Sleep 55 (TTE + L), OGC 1,250 (NA), SABE 1,863 (NA), SCDS 1,735 (NA), SLAS1 2,789 (NA), SLAS2 3,263 (NA), SOF 404 (L), Trelong 275 (L); subsequent 
stroke – BFC80+ 54 (TTE + L), CSHA 1,514 (NA), EAS 964 (TTE+L), HCS 882 (NA), HIMS 18 (TTE + L), HKOOS 1,540 (NA), ICARe Dicomano 634 (NA), ILSA 216 (TTE 
+ L), InveCe.Ab 203 (TTE + L), MAS 140 (TTE + L), MrMs Os 1 (TTE + L), MrOS Sleep 56 (TTE + L), OGC 1,250 (NA), SCDS 1,735 (NA), SABE 843 (L), SLAS1 2,789 (NA), 
SLAS2 3,263 (NA), SOF 6,591 (NA), Trelong 275 (L); number deceased – CSHA 1,57, EAS 4, HCS 8, HKOOS 83, ILSA 217, MrOS Sleep 101, SABE 173, SCDS23.
Abbreviations: GDS, Geriatric Depression Scale; MI, myocardial infarction; TIA, transient ischemic attack; ICARA, Initiative on Cardiovascular Disease Risk and Apathy.
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Table 2 Associations of apathy and depressive symptoms with subsequent myocardial infarction, stroke, and all-cause mortality
Myocardial infarction*
Model 1e Model 2f Model 3g
Events/total, n HR (95% CI) Events/total, n HR (95% CI) Events/total, n HR (95% CI)
Apathya 1,213/21,326 1.41 (1.25–1.58) 1,213/21,326 1.29 (1.15–1.45) 1,211/21,290 1.21 (1.08–1.36)
Apathy, isolatedb 861/14,467 1.46 (1.26–1.69) 861/14,467 1.31 (1.13–1.51) 859/14,446 1.24 (1.08–1.44)
Depressionc 1,204/21,129 1.14 (0.94–1.37) 1,204/21,129 1.11 (0.92–1.34) 1,202/21,094 1.08 (0.91–1.29)
Depression, isolatedd 682/13,870 1.17 (0.95–1.44) 682/13,870 1.17 (0.95–1.44) 681/13,852 1.14 (0.93–1.40)
Stroke**
Model 1e Model 2f Model 3g
Events/total, n HR (95% CI) Events/total, n HR (95% CI) Events/total, n HR (95% CI)
Apathya 1,449/23,284 1.62 (1.40–1.87) 1,449/23,284 1.43 (1.23–1.67) 1,449/23,232 1.37 (1.18–1.59)
Apathy, isolatedb 928/15,928 1.57 (1.37–1.80) 928/15,928 1.38 (1.2–1.58) 928/15,892 1.33 (1.15–1.52)
Depressionc 1,430/23,086 1.46 (1.26–1.70) 1,430/23,086 1.39 (1.20–1.61) 1,430/23,035 1.36 (1.18–1.56)
Depression, isolatedd 762/15,291 1.25 (1.04–1.50) 762/15,291 1.22 (1.01–1.46) 762/15,263 1.18 (0.99–1.42)
All-cause mortality***
Model 1e Model 2f Model 3g
Events/total, n HR (95% CI) Events/total, n HR (95% CI) Events/total, n HR (95% CI)
Apathya 15,615/46,802 1.75 (1.63–1.87) 15,612/46,796 1.52 (1.44–1.61) 11,984/38,898 1.47 (1.38–1.56)
Apathy, isolatedb 9,198/31,119 1.73 (1.65–1.82) 9,198/31,118 1.46 (1.40–1.53) 7,733/27,576 1.44 (1.36–1.51)
Depressionc 15,268/45,877 1.55 (1.43–1.67) 15,265/45,871 1.46 (1.37–1.56) 11,861/38,691 1.44 (1.35–1.53)
Depression, isolatedd 8,774/31,647 1.38 (1.27–1.50) 8,771/31,642 1.33 (1.25–1.42) 7,042/27,380 1.36 (1.28–1.44)
Notes: aScore ≥2 on the three-item apathy subscale of the Geriatric Depression Scale (GDS3A) and any depression score; bscore ≥2 on the GDS3A in participants with 
one or no depressive symptoms; cscore ≥2 on the 12-item depression subscale of the GDS (GDS12D) and any apathy score; dscore ≥2 on the GDS12D in participants with 
one or no apathy symptoms; eunadjusted; fadjusted for baseline age and sex; gadjusted for baseline age, sex, and history of myocardial infarction and/or stroke. Included in 
analysis: *models 1–3 – BFC80+, EAS, HIMS, ILSA, INVADE, L85+, MrMs Os, MrOS Sleep; **models 1–3 – BFC80+, EAS, HIMS, ILSA, INVADE, InveCe.Ab, L85+, MAS, MrMs 
Os, MrOS Sleep; ***models 1 and 2 – BFC80+, CSHA, EAS, HCS, HIMS, HKOOS, ICARe Dicomano (apathy analysis only because of unavailable depression scores), ILSA, 
INVADE, InveCe.Ab, L85+, MAS, MrMs Os, MrOS Sleep, OGC, SABE, SLAS1, SLAS2, SCDS, SOF, Trelong; model 3 – BFC80+, EAS, HIMS, ILSA, INVADE, InveCe.Ab, L85+, 
MAS, MrMs Os, MrOs Sleep, SCDS, SLAS1, SLAS2, SOF (unavailable history of myocardial infarction and/or stroke for the other studies).
Abbreviations: CI, confidence interval; HR, hazard ratio.
Figure 2 HRs for myocardial infarction, stroke, and all-cause mortality by apathy score in individuals without depressive symptoms.
Notes: Results from Cox proportional-hazard analyses with GDS3A score as predictor adjusted for baseline age, sex, and history of myocardial infarction and/or stroke in 
individuals without depressive symptoms (GDS12 score ≤1).
Abbreviation: GDS, Geriatric Depression Scale.
Trend HR: 1.11 P<0.001 Trend HR: 1.11 P<0.003 Trend HR: 1.24 P<0.001HR
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Discussion
In this IPD meta-analysis of a large sample of community-
dwelling older people, we found that apathy symptoms, 
irrespectively of concurrent depressive symptoms, were 
associated with a higher risk of MI, stroke, and all-cause CV 
and non-CV mortality. Depressive symptoms were related to 
a similarly increased risk of stroke and mortality outcomes, 
but not of MI. These observed associations were independent 
of age, sex, and history of MI/stroke.
The current study has several strengths. Large-scale 
meta-analysis of IP data is considered the “gold standard” 
for meta-analyses,18 reducing the potential for ecological bias 
compared to meta-analyses synthesizing individual study 
results.46 An assortment of studies were included with regard 
to country of origin and demographic characteristics, increas-
ing the generalizability of our findings. The risk of publication 
bias seems limited, given that none of the included studies 
originally aimed to assess the association between apathy 
symptoms and vascular outcomes or mortality. Nevertheless, 
publication bias of the relationship between depression and 
CVD could have indirectly influenced our results. Funnel 
plots of within-study associations, however, suggested the 
risk of publication bias playing a role in our findings is low. 
One-stage analyses were performed, which are recommended 
above two-stage methods, since their statistical approach is 
more exact, have more power for detection of interaction, 
and allow for better control of confounding and accounting 
for heterogeneity by allowing controlling for covariates at 
both the participant and study level.21,46 Finally, the data were 
extensively explored in a range of sensitivity and interaction 
analyses. 
Although it may be considered a limitation that the apathy 
and depression subscales have not been validated against a 
clinical diagnosis,10 the intention of our study was not to 
formally diagnose apathy and/or depression, but rather to 
explore whether degrees of apathy and depressive symptoms 
were differentially associated with future vascular disease and 
mortality. It is important to note that our results pertain to the 
symptoms in the GDS15, and may not be generalizable to 
all depressive and apathy symptoms in a clinical interview. 
Table 3 Two-stage analyses of associations of apathy and depressive symptoms with subsequent myocardial infarction, stroke, and 
all-cause mortality
Myocardial infarction*
Model 1e Model 2f Model 3g
HR (95% CI) I2 HR (95% CI) I2 HR (95% CI) I2
Apathya 1.40 (1.24–1.59) 5 1.28 (1.10–1.49) 18 1.21 (1.05–1.40) 13
Apathy, isolatedb 1.52 (1.26–1.84) 19 1.41 (1.13–1.76) 33 1.35 (1.07–1.71) 37
Depressionc 1.16 (0.96–1.39) 28 1.15 (0.97–1.36) 21 1.12 (0.95–1.31) 12
Depression, isolatedd 1.21 (0.99–1.49) 0 1.21 (0.98–1.49) 0 1.18 (0.96–1.46) 0
Stroke**
Model 1e Model 2f Model 3g
HR (95% CI) I2 HR (95% CI) I2 HR (95% CI) I2
Apathya 1.71 (1.54–1.91) 0 1.49 (1.32–1.69) 10 1.45 (1.3–1.61) 0
Apathy, isolatedb 1.59 (1.39–1.83) 0 1.39 (1.21–1.60) 0 1.34 (1.17–1.54) 0
Depressionc 1.55 (1.29–1.75) 26 1.44 (1.25–1.66) 17 1.43 (1.27–1.60) 0
Depression, isolatedd 1.3 (1.08–1.56) 1 1.27 (1.05–1.52) 0 1.24 (1.03–1.49) 0
All-cause mortality***
Model 1e Model 2f Model 3g
HR (95% CI) I2 HR (95% CI) I2 HR (95% CI) I2
Apathya 1.73 (1.62–1.85) 68 1.52 (1.44–1.60) 48 1.46 (1.38–1.56) 47
Apathy, isolatedb 1.72 (1.63–1.81) 9 1.46 (1.39–1.53) 0 1.44 (1.36–1.51) 0
Depressionc 1.54 (1.43–1.67) 77 1.46 (1.37–1.56) 67 1.44 (1.35–1.53) 50
Depression, isolatedd 1.39 (1.27–1.52) 58 1.33 (1.25–1.43) 32 1.38 (1.3–1.46) 0
Notes: Results from two-stage analyses by pooling results of Cox proportional-hazard analyses within individual studies using DerSimonian and Laird random-effect models 
(forest plots in Figures S1–S3). aScore ≥2 on the three-item apathy subscale of the Geriatric Depression Scale (GDS3A) and any depression score; bscore ≥2 on the GDS3A 
in participants with one or no depressive symptoms; cscore ≥2 on the 12-item depression subscale of the GDS (GDS12D) and any apathy score; dscore ≥2 on the GDS12D 
in participants with one or no apathy symptoms; eunadjusted; fadjusted for baseline age and sex; gadjusted for baseline age, sex, and history of myocardial infarction and/
or stroke. Included in analysis: *models 1–3 – BFC80+, EAS, HIMS, ILSA, INVADE, L85+, MrMs Os, MrOS Sleep; **models 1–3 – BFC80+, EAS, HIMS, ILSA, INVADE, 
InveCe.Ab, L85+, MAS, MrMs Os, MrOS Sleep; ***models 1 and 2 – BFC80+, CSHA, EAS, HCS, HIMS, HKOOS, ICARe Dicomano (apathy analysis only because of unavailable 
depression scores), ILSA, INVADE, InveCe.Ab, L85+, MAS, MrMs Os, MrOS Sleep, OGC, SABE-Brazil, SLAS1, SLAS2, SCDS, SOF, Trelong; model 3 – BFC80+, EAS, HIMS, 
ILSA, INVADE, InveCe.Ab, L85+, MAS, MrMs Os, MrOs Sleep, SCDS, SLAS1, SLAS2, SOF (unavailable history of myocardial infarction and/or stroke for the other studies).
Abbreviation: GDS, Geriatric Depression Scale
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We could not adjust for all potential confounders, including 
(chronic) vascular comorbidity, functional and cognitive 
impairment, socioeconomic status, and education, potentially 
leading to residual confounding. However, adjustment for 
some of these characteristics could have led to overadjust-
ment, since they could also function as mediators. We tried 
to reduce the risk that individuals with severe cognitive and 
functional impairment were included in our analyses by 
excluding institutionalized individuals. In addition, several 
studies have found associations of apathy in older people 
with adverse outcomes independently of disability and 
cognition.11,16,47 
Although we were able to acquire IPD for a large number 
of older people, more than half the eligible studies did not 
participate. These studies seemed to have slightly different 
population characteristics, suggesting that not including 
their data may have had some impact on our results. Non-
participating studies were smaller, had more women, and 
slightly older populations. Since older age was a mediator 
of the associations with apathy symptoms, inclusion of 
these older cohorts could have decreased the magnitude 
of the unadjusted associations. Furthermore, although we 
incorporated studies from all over the world, more variety in 
population provenance may have allowed investigation into 
how geography affects these relations, since it has been shown 
that the exact construct of apathy symptoms within the GDS 
may differ among cultures.48 Finally, since we did not have 
longitudinal data regarding the development of apathy and 
depressive symptoms over time, we cannot ascertain whether 
their stability has an influence on the risk of subsequent 
unfavorable clinical outcomes.
That apathy symptoms in this IPD meta-analysis were 
associated with subsequent MI (and also PA and PAD) inde-
pendently of depressive symptoms corroborates our previous 
report of a specific association for apathy symptoms with an 
increased risk of CVD11 and concurs with the vascular apathy 
hypothesis.12 This IPD meta-analysis is (to our knowledge) 
the first to study the association between apathy symptoms 
and subsequent MI systematically. Previous studies assessing 
the reverse association consistently reported that a history of 
vascular disease predicted greater apathy, but not depression 
scores.12,49 That apathy symptoms are specifically associated 
with future MI is in line with findings in other studies that 
suggest that motivation-related somatic rather than mood-
related depressive symptoms are related to adverse CV 
outcomes in older individuals.6,50,51 We found no association 
between depressive symptoms and future MI, which may be 
contrary to results of several traditional meta-analyses.1–4 
However, since no discrimination was made between apathy 
and depressive symptomatology in these studies, it is possible 
that those associations were at least partly driven by apathy.
Both apathy and depressive symptoms were associated 
with a an approximately 37%-higher risk of future stroke. 
This is contrary to our previous single-cohort study, in 
which no associations between either apathy or depressive 
symptoms and higher future stroke risk were found.11 This 
discrepancy can most likely be explained by the far greater 
statistical power of the current analysis. In addition, the pres-
ent study population was slightly younger on average, and 
both our own results and the previous literature suggest that 
the relationship between depressive symptoms and future 
stroke is stronger in younger people.52,53 The association 
of depressive symptoms with future stroke is in line with 
several meta-analyses that – although not distinguishing 
between apathy and depressive symptoms – have shown 
that depression and somewhat less so depressive symptoms 
are independent risk factors for stroke, increasing the risk 
by 20%–45%.52–55
We found an approximately 45% higher hazard for both 
apathy and depressive symptoms with all-cause mortality. A 
similarly increased risk of mortality in people with depression 
has been demonstrated by several studies.56–59 Studies that 
have examined the relation between apathy symptoms and 
mortality in general community-dwelling older populations 
are sparse, employed different methods of apathy assessment, 
and mostly studied specific populations, eg, those with frailty, 
heart disease, or dementia.60–64
The mechanisms by which apathy and depressive symp-
toms are related to future adverse vascular outcomes are 
unknown. Conceivably, both causal and noncausal effects 
play a role. Deleterious health behaviors and CV-risk fac-
tors may be induced by apathy and depression and thus 
partly mediate the reported associations with unfavorable 
outcomes.65–70 Other mediators may also be of influence, eg, 
reduced compliance with CV-risk management.70 Alterna-
tively, the observed associations may be due to a common 
etiology underlying vascular disease, apathy, and depressive 
symptoms. It is imaginable that apathy and/or depressive 
symptoms are markers of underlying subclinical (cerebral) 
atherosclerosis, which is a strong risk factor for vascular 
events.70 Previous studies have associated apathy and depres-
sive symptoms with the presence of white-matter lesions 
in older individuals, also without clinical depression.71–75 
Although our previous research suggests that the relation-
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ship between apathy symptoms and future vascular events 
is independent of CV-risk factors,11,67 conceivably apathy 
symptoms reflect cerebrovascular damage by long-standing 
elevated CV risk, eg, midlife hypertension. If apathy is indeed 
a marker of cerebrovascular damage, such risk factors could 
be considered confounders underlying the relation between 
apathy and incident disease. Furthermore, although apathy 
predicts future vascular events independently of vascular 
event history, vascular events are a risk factor for apathy. 
This suggests that the temporal relationship between apathy 
and vascular events could be bidirectional, corresponding 
with previous findings that apathy symptoms can also be 
preceded by CVD.12
Our finding that symptoms of apathy gave an approxi-
mately 20% increased hazard of MI, while depressive 
symptoms did not seem clearly to increase this hazard, may 
have several explanations. Apathy symptoms may be more 
specific markers of underlying cerebrovascular disease, as 
suggested by the stronger relation with incident stroke, and 
thus more strongly associated with other incident vascular 
disease. Alternatively, apathy symptoms may be more sensi-
tive to prodromal CV disease, since individuals with poor CV 
condition may tend to be less outgoing and feel less energetic. 
The relationship among apathy and depressive symptoms 
and mortality may be mediated by the increased occurrence 
of major vascular events, including MI and stroke, which 
are among the most important causes of death worldwide.76 
Alternatively, both types of symptoms could be manifesta-
tions of other underlying conditions that give a higher risk 
of mortality.
The dose-response relationship between apathy symp-
toms and subsequent stroke, MI and mortality, independent 
of depressive symptoms, together with previous analyses 
suggesting that apathy predicts CVD over and above the 
presence of CV-risk factors,67 stress that recognition of apathy 
symptoms in older people is important, regardless of depres-
sive symptoms. Although apathy symptoms may manifest 
themselves in the context of depression, our research adds 
to the expanding body of evidence highlighting apathy as an 
important standalone syndrome.8,12,49,67,77–81 Distinct associa-
tions were found between apathy symptoms and a number 
of patient-important CV outcomes, including MI, AP, and 
PAD. Participants with two or more apathy symptoms had a 
20%–30%-increased risk of these outcomes, independently 
of concurrent depressive symptoms. Individuals with a 
maximum apathy score (10.6% of our study population) had 
an 88% increased hazard of mortality. These findings imply 
that more attention on recognizing, detecting, and managing 
apathy in general practice is warranted. This is especially 
relevant, since patients with apathy are less likely to engage 
actively in CV-risk prevention and health care.82 
It is also important to recognize apathy as an entity 
distinct from depression, since treatment with selective 
serotonin-reuptake inhibitors (SSRIs) has not only been 
found to be ineffective but could also potentially aggravate 
apathy.83–85 Given the common and potentially serious side 
effects of SSRI treatment in older people, this is especially 
undesirable.86,87 If treatment of symptoms could mitigate 
the increased risks, based on the risks in the symptom-free 
populations and fully adjusted models, successful apathy 
treatment could decrease the absolute 5-year risks for these 
individuals from 4.7% to 3.9% for MI and from 5.8% to 4.2% 
for stroke. Depressive-symptom treatment would decrease 
these risks by 5.0% to 4.6% for MI and from 6.5% to 4.8% 
for stroke. Increased awareness of apathy in research settings 
is instrumental in elucidating its specific etiological role 
in CV disease and increasing the knowledge of its clinical 
correlates.
In conclusion, this IPD meta-analysis provides substantial 
evidence that apathy symptoms in community-dwelling older 
people are associated with an increased risk of future stroke, 
MI, and mortality, independently of concurrent depressive 
symptoms. It suggests depressive symptoms are associated 
with a similarly increased risk of stroke and mortality, but 
not substantially of MI. These independent associations 
between apathy symptoms and patient-important outcomes 
stress the necessity of recognizing apathy in older people 
independently of depressive symptoms. Future studies may 
investigate whether these associations are specific for apathy 
symptoms according to the GDS or also apply similarly to 
apathy and depressive symptoms according to other scales. 
Future research could evaluate the effects of change in the 
presence of these symptoms over time, aim at unraveling 
the mechanisms underlying their associations with adverse 
outcomes in later life, and examine whether interventions can 
prevent or reduce their occurrence and clinical consequences.
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